about
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signatureEZH2 in normal hematopoiesis and hematological malignanciesOsteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients.A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategyInput of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia.SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma.Characterization of human FCRL4-positive B cells.RECQ helicases are deregulated in hematological malignancies in association with a prognostic valueGene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors.Differential effects of lenalidomide during plasma cell differentiationIdentifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myelomaClinical and prognostic role of annexin A2 in multiple myeloma.SULFs in human neoplasia: implication as progression and prognosis factors.Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells.APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.Induction of angiogenesis by normal and malignant plasma cells.TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma.Embryonic stem cell markers expression in cancers.Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis.Loss of RASSF4 expression in multiple myeloma promotes RAS-driven malignant progression.Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion.Hypoxia favors the generation of human plasma cells.DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy.Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients.PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDsDNA repair in diffuse large B-cell lymphoma: a molecular portraitOverexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent mannerComprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistanceInhibition of Ataxia-Telangiectasia Mutated and RAD3-Related () Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal CancerCD200: a putative therapeutic target in cancerNPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm
P50
Q24647037-51601912-BA74-4223-8EE6-9B6A9399B073Q26779821-E26A2CA1-AD82-4029-BD33-EC128ED153DBQ33564854-B4C2E2FA-59BD-4DC8-BDF8-9FA8E7ED932EQ33634389-6FF86A14-CAD7-4E75-AE19-388A735B35CAQ33757020-C0D13A5F-EDAA-4046-89DD-819B8D718882Q34022979-911EDF2C-4272-47E0-9BA0-40B439B66CF3Q35116374-95287DEE-445D-45CC-AB87-7C14906CC2EAQ35162589-3705FED1-3AED-4B62-8FD9-61A8BBF2A3F6Q35797736-64586F55-9DD0-40BE-890B-F08346C1A92FQ36411427-F1C90E56-1341-40C0-8144-00B562E1196FQ36577713-07647085-9630-4F7B-B5D2-F78120087975Q37083880-A2143369-711A-45E9-ADB3-BB874A648C33Q37317494-B1255D5D-8C2B-4968-A701-A6FC90DF3856Q38694866-029F5292-AD3B-41EC-BE37-4C3691B25371Q38910971-8D2889CC-0492-4E4A-BBC6-6C60EDAF48E0Q38967891-49DD8E2F-44DF-448E-849C-A2B61EADEE7EQ39330092-0C0F7A91-F730-444F-B259-2BBF9BB1EA19Q39390171-4A63FF70-9CCB-4C0D-A800-18C748F2F1C9Q39395605-600EC9DC-90A0-4050-AEE2-F3DD89C0FF74Q39849215-45882A84-76BF-4799-8C86-75DC0D332D50Q39870744-997D20D7-7770-493E-AD26-E1F98DF4EC49Q42960413-F4F8F4F8-72DF-412A-8276-D6F7F23EF821Q43067059-F9140650-C137-4D2C-B6B3-39B606BC29ABQ43717864-833FE17A-1881-49D0-A952-86B9B43508CEQ46553640-AE232742-B411-44EB-8202-5EAAE7CC6CAAQ47273607-32213BE5-E406-4E23-85B3-6E50EDBECF9CQ47281717-84EFF5F1-08A5-4B21-BFF9-5B9E73BCDC43Q47807293-DAFBFCAF-187C-44B6-8CFA-1C21C2FA3399Q48207902-F3BD4E7F-ED5E-404E-9663-4A87BE9CB5B8Q52676395-7E8ADD0A-F682-4CF4-ABD4-760122DFE2B8Q54528284-1019120C-2974-4B01-BB85-E94990A3DCC6Q55106924-31BCEC55-8893-441B-A1AC-CBC3D8C308B5Q55429006-EE5BE77D-A1E7-4D6B-A50F-86984FFAF216Q57035464-0585485A-A4B9-4F80-BF79-EB62447411FFQ63965581-5660DC01-952A-4FEF-ADC9-6DCA54427EBDQ64113941-5D1FD68F-2B37-40D5-BA0B-CD38E374E1A8Q64244656-3B0A71D2-8C17-4B0C-A8E7-7EF35C4367F2Q64387238-9786ECF9-5A86-465E-BB05-6C75B89141D9Q80149925-2897B4CE-9021-4470-AD81-25B068DFF0FDQ82510141-9ABC7169-A628-4764-A804-7FF628E2E391
P50
description
researcher ORCID ID = 0000-0002-5717-3207
@en
wetenschapper
@nl
name
Jerome Moreaux
@ast
Jerome Moreaux
@en
Jerome Moreaux
@es
Jerome Moreaux
@nl
Jérôme Moreaux
@fr
type
label
Jerome Moreaux
@ast
Jerome Moreaux
@en
Jerome Moreaux
@es
Jerome Moreaux
@nl
Jérôme Moreaux
@fr
altLabel
Moreaux J
@en
prefLabel
Jerome Moreaux
@ast
Jerome Moreaux
@en
Jerome Moreaux
@es
Jerome Moreaux
@nl
Jérôme Moreaux
@fr
P214
P227
P269
P101
P106
P2002
moreauxjerome
P2038
Jerome_Moreaux
P21
P213
0000 0003 5711 3156
P214
P227
1158626851
P269
P2798
P31
P4012
P496
0000-0002-5717-3207
P569
1979-01-01T00:00:00Z
P6634
jerome-moreaux-4475a89
P7859
viaf-193848232